Phase II study of acivicin as a 72-hr continuous infusion in patients with untreated colorectal cancer. A National Cancer Institute of Canada Clinical Trials Group Study.
The National Cancer Institute of Canada (NCIC) Clinical Trials Group has carried out a phase II study of acivicin given as a 72-hour continuous infusion in previously untreated patients with measurable metastatic colorectal carcinoma. Toxicity in 24 patients was mild to moderate and consisted primarily of GI symptoms such as nausea, vomiting, diarrhea or CNS changes including drowsiness, lethargy, dizziness. No responses were seen in 23 evaluable patients. We did not find acivicin given as described to be effective in colorectal carcinoma.
Eisenhauer
E A
EA
NCIC Clinical Trials Group, Queen's University, Kingston, Ontario, Canada.
Maroun
J A
JA
Fields
A L
AL
Walde
P L
PL
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002170:Canada; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010080:Oxazoles / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D007555:Isoxazoles; D010080:Oxazoles; C006303:acivicin